Efficacy and Safety of Baricitinib in Sjogren's Syndrome

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 14, 2022

Primary Completion Date

August 22, 2024

Study Completion Date

November 22, 2024

Conditions

Sjogren's Syndrome

Interventions

DRUG

Baricitinib

baricitinib 4mg per day

DRUG

Hydroxychloroquine

Hydroxychloroquine 200mg twice a day

Trial Locations (1)

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

lead

Peking Union Medical College Hospital

OTHER